Revolution Medicines (RVMD) CEO trades stock under preset 10b5-1 plan
Revolution Medicines (RVMD) CEO Mark Goldsmith exercised options for 80,000 shares at $4.73 each and sold 86,000 shares at $206.78-$212.74 under a 10b5-1 plan, generating $17.99M in proceeds. Transactions included sales through revocable trusts. Goldsmith's holdings post-transaction include 344,085 stock options and 267,330 common shares directly, plus 655,484 shares indirectly.
How this was made
The 30-second read
Why it matters
The disclosed sale provides fresh data on insider sentiment, potentially influencing short‑term trading decisions.
Market read
A sizable insider sell in a micro‑cap biotech could trigger short‑term price pressure.
What to watch
The sale was executed under a pre‑established 10b5‑1 plan, which can mitigate negative signaling.
Background
Form 4 filing reveals insider transactions; such disclosures are primary sources for insider activity.
Ticker impact
CEO Mark Goldsmith exercised 80,000 options at $4.73 and sold 86,000 shares for $17.99M under a 10b5-1 plan, disclosed in a Form 4 filing.
Possible near-term price decline as market digests large insider sale.
The sale size ($18M) is material for a micro‑cap biotech and was disclosed for the first time via a Form 4, providing fresh actionable information.
Market effects
May raise concerns about insider sentiment in the biotech sector.
Limited to U.S. biotech investors.
Low global impact.
Counterpoint
Insider sales can be routine liquidity events; the CEO may have diversified personal holdings without negative outlook.
Key entities
- personMark A. Goldsmith
CEO of Revolution Medicines, executed the insider sale.
- companyRevolution Medicines, Inc.
Biotech company listed on Nasdaq under ticker RVMD.
